Results 171 to 180 of about 95,261 (258)

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

open access: yesMedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng   +8 more
wiley   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem   +9 more
wiley   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang   +7 more
wiley   +1 more source

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. [PDF]

open access: yesCell Death Dis
Asmanidou S   +15 more
europepmc   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen   +3 more
wiley   +1 more source

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao   +5 more
wiley   +1 more source

Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Length Recombinant Bcl-xL Monomers. [PDF]

open access: yesChembiochem
Elsner C   +6 more
europepmc   +1 more source

Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders

open access: yesNeuroprotection, Volume 4, Issue 1, Page 30-47, March 2026.
The graphical abstract encapsulates the dual neuroprotective mechanisms of statins in neurodegenerative diseases, highlighting both cholesterol‐dependent and cholesterol‐independent pathways. By inhibiting 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, statins reduce cholesterol synthesis, leading to altered lipid raft structures that ...
Jun Han Kuan   +5 more
wiley   +1 more source

Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry. [PDF]

open access: yesChem Sci
Gadallah MI   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy